Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Phase 3

Active, not recruiting

• Conditions: Metastases
• Interventions: Drug: Leuprorelin Acetate

• Registration Number: NCT01442246
• Lead Sponsor: UNICANCER

Brief Summary

PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence.

SECONDARY OBJECTIVE(S):

* PSA evolution

* Evaluation of testosterone level

* Specific survival

* Overall survival

* Tolerance

* Quality of life (QLQ-C30 questionnaires)

Detailed Description

Not available

Study Timeline

• Study Start: 2011-07
• Study First Submitted: 2011-09-27
• Study First Submitted QC: 2011-09-27
• Study First Posted: 2011-09-28
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-20
• Last Update Posted: 2023-06-22
• Primary Completion: 2027-09
• Study Completion: 2027-09

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Male
• Target Recruitment: 700

Inclusion Criteria

1. Patients who have received the information leaflet and signed the consent form

2. ≥18 years of age with a life expectancy of at least 10 years

3. Performance Status (ECOG) ≤2

4. Radical prostatectomy (RP) with or without extended pelvic lymphadenectomy in the 3 months preceding inclusion

5. Histologically confirmed prostatic adenocarcinoma

6. Patients R0, N0 or Nx or N+ (≤ 2 nodes among nodes removed), M0 and with at least one of the following criteria:

   • postoperative Gleason score >7
   • postoperative Gleason score =7 with the presence of high-grade Gleason patterns
   • pT3b patients

7. Postoperative PSA <0.1 ng/mL (dosage perform within 2 months after surgery)

8. Neutrophils ≥1500/mm³, platelets ≥100000/mm³

9. Bilirubin ≤ upper normal limit (this will not apply to subjects with Gilbert's syndrome, persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology); ASAT and ALAT ≤1.5 times upper normal limit; Creatinine <140 µmol/l (or clearance >60 mL/min)

10. Patients affiliated to a social security scheme

Exclusion Criteria

1. Previous treatments for prostatic adenocarcinoma (HT or orchiectomy or CT)

2. Presence of metastases:

   • positive bone scintigraphy, including Patients with medullary compression and/or
   • abdominal-pelvic CT scan or MRI showing lymph node and/or visceral involvement

3. History of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission

4. Incompatible concomitant treatment(s)

5. Hypersensitivity to other GnRH agonists and/or any of the excipients of Eligard®

6. Any illness or problem including geographic, psychiatric or psychological which is incompatible with being monitored during the trial

7. Persons deprived of their freedom or under supervision (including guardianship),

8. Patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Adjuvant treatment	Leuprorelin Acetate	Leuproreline acetate

Primary Outcome Measures

Name	Time	Method
The principal criterion is the evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy.	The principal criterion will be evaluated 12 years after the inclusion of the first patient.

Trial Locations

Locations (35)

Chu Bordeaux- Hopital Pellegrin; 🇫🇷 Bordeaux, France

Clinique Victor Pauchet; 🇫🇷 Amiens, France

Chu Besancon; 🇫🇷 Besancon, France

Institut Bergonie; 🇫🇷 Bordeaux, France

Chru de Brest; 🇫🇷 Brest, France

Chu Bocage; 🇫🇷 Dijon, France

Centre Hospitalier Departemental; 🇫🇷 La Roche Sur Yon, France

Hopital Henri Mondor; 🇫🇷 Creteil, France

Chru Lille; 🇫🇷 Lille, France

Institut Paoli Calmettes; 🇫🇷 Marseille, France

Clinique Beausoleil; 🇫🇷 Montpellier, France

Chu de Nancy; 🇫🇷 Nancy, France

Chu Nantes; 🇫🇷 Nantes, France

Hopital Lapeyronie; 🇫🇷 Montpellier, France

Chu Caremeau; 🇫🇷 Nimes, France

Hopital Saint Louis; 🇫🇷 Paris, France

HEGP; 🇫🇷 Paris, France

Hopital Cochin; 🇫🇷 Paris, France

Hopital Tenon; 🇫🇷 Paris, France

Hopital Charles Nicolle; 🇫🇷 Rouen, France

Clinique Mutualiste; 🇫🇷 Saint Etienne, France

Centre Hopsitalier Prive - Polyclinique Du Littoral; 🇫🇷 Saint Brieuc, France

Chu Pontchaillou; 🇫🇷 Rennes, France

Hopital Foch; 🇫🇷 Suresnes, France

Chu Rangueil; 🇫🇷 Toulouse, France

Chu Strasbourg; 🇫🇷 Strasbourg, France

Hopital Edouard Herriot; 🇫🇷 Lyon, France

Chu Limoges; 🇫🇷 Limoges, France

Chu Pasteur; 🇫🇷 Nice, France

Institut Mutualiste Montsouris; 🇫🇷 Paris, France

Chu La Miletrie; 🇫🇷 Poitiers, France

Institut Jean Godinot; 🇫🇷 Reims, France

Hopitaux Civils de Colmar; 🇫🇷 Strasbourg, France

Hopital Nord; 🇫🇷 Marseille, France

Hopital Pitie Salpetriere; 🇫🇷 Paris, France